Impel NeuroPharma, Inc. (IMPL)
|Net Income (ttm)||n/a|
|Trading Day||July 29|
|Day's Range||12.63 - 14.20|
|52-Week Range||6.90 - 15.89|
Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patien...
– Completed successful IPO raising approximately $80.0 million in gross proceeds – – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 – – Stre...
Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Co...
Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine Initiative Features Artwork from Internationally Renowned Art...
The news: Seattle-based biotech company Impel NeuroPharma raised $80 million in its initial public offering and will begin trading on the NASDAQ Friday.
SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformati...
Impel NeuroPharma has filed to raise $75 million in an IPO to bring a migraine drug to market. The candidate, Trudhesa, is delivered using a metered dose device intended to get the active ingredient int...
Impel NeuroPharma, Inc. has filed to go public with an IPO on the NASDAQ.
Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.
Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. We have designed our proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology to target the vascular-rich upper nasal cavity, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, pro... [Read more...]
|IPO Date |
Apr 23, 2021
|Stock Exchange |
|Ticker Symbol |